Johnson & Johnson (JNJ) - NYSE
  • Tue, Jul. 19, 8:05 AM
    • Johnson & Johnson (NYSE:JNJ) Q2 results ($M): Total Revenues: 18,482 (+3.9%); Consumer: 3,419 (-1.8%); Pharmaceutical: 8,654 (+8.9%); Medical Devices & Diagnostics: 6,409 (+0.8%).
    • Sales By Region: U.S.: 9,572 (+7.4%); Europe: 4,090 (-1.5%); W. Hemisphere ex-U.S.: 1,542 (+2.7%); Asia Pacific & Africa: 3,278 (+1.7%).
    • Sales By Business: OTC: 1,008 (+3.5%); Immunology: 3,038 (+19.0%); Infectious Diseases: 829 (-19.7%); Neuroscience: 1,602 (+2.4%); Oncology: 1,474 (+28.8%); Cardiovascular/Metabolism/Other: 1,711 (+3.6%); Medical Devices & Diagnostics: 6,409 (+0.8%).
    • Key Product Sales: Remicade: 1,780 (+6.7%); Stelara: 804 (+41.1%); Zytiga: 601 (+10.1%); Xarelto: 594 (+25.8%).
    • 2016 Guidance: Total Revenues: $71.5B - 72.2B from $71.2B - 71.9B; Non-GAAP EPS: $6.63 - 6.73 from $6.53 - 6.68.
    • Shares are up 3% premarket on increased volume.
    | Tue, Jul. 19, 8:05 AM | 3 Comments
  • Tue, Jul. 19, 6:42 AM
    • Johnson & Johnson (NYSE:JNJ): Q2 EPS of $1.74 beats by $0.06.
    • Revenue of $18.48B (+3.9% Y/Y) beats by $500M.
    • Shares +1.51% PM.
    • Press Release
    | Tue, Jul. 19, 6:42 AM | 27 Comments
  • Mon, Jul. 18, 5:30 PM
    | Mon, Jul. 18, 5:30 PM | 6 Comments
  • Tue, Apr. 19, 7:45 AM
    • Johnson & Johnson (NYSE:JNJ) Q1 results ($M): Total Revenues: 17,482 (+0.6%); Consumer: 3,195 (-5.8%); Pharmaceutical: 8,178 (+5.9%); Medical Devices & Diagnostics: 6,109 (-2.4%).
    • Revenues by region: U.S.: 9,321 (+7.2%); Europe: 3,847 (-4.8%); W. Hemisphere ex-U.S.: 1,331 (-18.8%); Asia Pacific & Africa: 2,983 (-0.7%).
    • Strong growers: Oncology: 1,354 (+22.2%); Immunology: 2,910 (+18.1%).
    • Key product sales: Imbruvica: 261 (+125.0%); Stelara: 735 (+33.9%); Simponi/Simponi Aria: 390 (+30.0%); Xarelto: 567 (+28.6%).
    • Weak areas: Infectious Diseases: 776 (-20.4%); Consumer: 3,195 (-5.8%); Neuroscience: 1,549 (-4.3%).
    • Pre-Tax Earnings: 5,294 (-5.0%); Non-GAAP Pre-Tax Earnings: 5,801 (+3.0%); Net Income: 4,292 (-0.6%); Non-GAAP Net Income: 4,689 (+6.1%); EPS: 1.54 (+0.7%); Non-GAAP EPS: 1.68 (+7.7%).
    • 2016 Guidance: Total Revenues: $71.2B - 71.9B; Non-GAAP EPS: $6.53 - 6.68.
    • Read now Johnson & Johnson In A Quandary 
    | Tue, Apr. 19, 7:45 AM | 3 Comments
  • Tue, Apr. 19, 6:43 AM
    • Johnson & Johnson (NYSE:JNJ): Q1 EPS of $1.68 beats by $0.02.
    • Revenue of $17.48B (+0.6% Y/Y) misses by $20M.
    • Press Release
    | Tue, Apr. 19, 6:43 AM | 17 Comments
  • Mon, Apr. 18, 5:30 PM
    | Mon, Apr. 18, 5:30 PM | 3 Comments
  • Tue, Jan. 26, 7:24 AM
    • Johnson & Johnson (NYSE:JNJ) Q4 results ($M): Total Revenues: 17,811 (-2.4%); Consumer: 3,320 (-7.9%); Pharmaceutical: 8,064 (+0.8%); Medical Devices & Diagnostics: 6,427 (-3.3%).
    • Revenues by region: U.S.: 9,293 (+8.0%); Europe: 4,002 (-12.2%); W. Hemisphere ex-U.S.: 1,442 (-19.1%); Asia Pacific & Africa: 3,074 (-7.1%).
    • Sample of sales by product/segment: OTC: 1,045 (-2.6%); Remicade: 1,680 (+0.5%); Orthopedics: 2,423 (-0.7%); Surgery: 2,413 (-2.5%); Stelara: 742 (+36.1%).
    • Net Income: 3,215 (+27.5%), EPS: 1.15 (+29.2%); Non-GAAP Net Income: 4,043 (+11.9%); Non-GAAP EPS: 1.44 (+5.1%).
    • 2016 Guidance: Revenues: $70.8 - 71.5B; Non-GAAP EPS: $6.43 - 6.58.
    | Tue, Jan. 26, 7:24 AM | 18 Comments
  • Tue, Jan. 26, 6:46 AM
    • Johnson & Johnson (NYSE:JNJ): Q4 EPS of $1.44 beats by $0.02.
    • Revenue of $17.81B (-2.4% Y/Y) misses by $70M.
    | Tue, Jan. 26, 6:46 AM | 5 Comments
  • Mon, Jan. 25, 5:30 PM
    | Mon, Jan. 25, 5:30 PM | 13 Comments
  • Oct. 13, 2015, 8:06 AM
    • Johnson & Johnson (NYSE:JNJ) Q3 results ($M): Total Revenues: 17,102 (-7.4%); Consumer: 3,314 (-7.7%); Pharmaceutical: 7.694 (-7.4%); Medical Devices & Diagnostics: 6,094 (-7.3%).
    • Revenues by Region: U.S.: 8,791 (-0.6%); Europe: 3,802 (-14.5%); W. Hemisphere ex-U.S.: 1,463 (-19.6%); Asia Pacific & Africa: 3,046 (-9.3%).
    • Net Income: 3,358 (-29.3%); EPS: 1.20 (-27.7%); Non-GAAP EPS: 1.49 (-0.7%).
    • Key Product Sales: Remicade: 1,613 (-9.5%); Stelara: 613 (+12.9%); Invega Sustenna/Xeplion: 459 (+13.9%); Zytiga: 548 (-3.5%); Xarelto: 461 (+11.4%); Invokana/Invokamet: 340 (+392.8%).
    • 2015 Guidance: EPS: $6.15 - 6.20 from $6.10 - 6.20.
    | Oct. 13, 2015, 8:06 AM | 8 Comments
  • Oct. 13, 2015, 7:32 AM
    • Johnson & Johnson (NYSE:JNJ): Q3 EPS of $1.49 beats by $0.04.
    • Revenue of $17.1B (-7.4% Y/Y) misses by $350M.
    | Oct. 13, 2015, 7:32 AM | 18 Comments
  • Oct. 12, 2015, 5:30 PM
  • Oct. 12, 2015, 12:26 PM
    • Johnson & Johnson (JNJ +0.8%) reports Q3 results tomorrow morning before the open. The conference call begins at 8:30 am ET. Consensus view is EPS of $1.45 (-12.7%) on revenues of $17.5B (-5.2%).
    | Oct. 12, 2015, 12:26 PM | 2 Comments
  • Jul. 14, 2015, 8:26 AM
    • Johnson & Johnson (NYSE:JNJ) Q2 results ($M): Total Revenues: 17,787 (-8.8%); Consumer: 3,483 (-7.0%); Pharmaceutical: 7,946 (-6.6%); Medical Devices & Diagnostics: 6,358 (-12.2%).
    • Revenue by Region: U.S.: 8,911 (-2.4%); Europe: 4,151 (-17.9%); Western Hemisphere ex-U.S.: 1,501 (-19.4%); Asia Pacific & Africa: 3,224 (-6.4%).
    • Total revenue growth has decelerated over the past four quarters: +9.1%, +5.1%, -0.6%, -4.1%, -8.8%.
    • Pharma unit revenue growth has decelerated the past four quarters: +21.1%, +18.1%, +9.6%, +3.0%, -6.6%.
    • Operating earnings growth has also decelerated over the past four quarters: +17.8%, +14.4%; -3.1%; -5.3%; -17.6%.
    • EPS guidance raised to $6.10 - 6.20.
    | Jul. 14, 2015, 8:26 AM | 17 Comments
  • Jul. 14, 2015, 7:47 AM
    • Johnson & Johnson (NYSE:JNJ): Q2 EPS of $1.71 beats by $0.03.
    • Revenue of $17.79B (-8.8% Y/Y) beats by $30M.
    | Jul. 14, 2015, 7:47 AM
Company Description
Johnson & Johnson operates as an investment holding company with interests in health care products. It engages in research and development, manufacture and sale of personal care hygienic products, pharmaceuticals and surgical equipment. The company, through its subsidiaries operates in three... More
Sector: Healthcare
Industry: Drug Manufacturers - Major
Country: United States